Yalonda Howze - 16 Feb 2022 Form 4 Insider Report for Codiak BioSciences, Inc.

Role
Officer title: Executive Vice President, Chief Legal and Compliance Officer and Corporate Secretary
Signature
/s/ Yalonda Howze
Issuer symbol
N/A
Transactions as of
16 Feb 2022
Net transactions value
$0
Form type
4
Filing time
18 Feb 2022, 15:05:55 UTC
Previous filing
21 Jan 2022
Next filing
21 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CDAKQ Stock Option (Right to Buy) Award $0 +12,950 $0.000000 12,950 16 Feb 2022 Common Stock 12,950 $5.21 Direct F1
transaction CDAKQ Restricted Stock Units Award $0 +19,425 $0.000000 19,425 16 Feb 2022 Common Stock 19,425 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option shall vest and become exercisable on February 16, 2023, with the remainder vesting in 12 equal quarterly installments thereafter.
F2 Each restricted stock unit represents a contingent right to receive one share of common stock.
F3 On February 16, 2022, the reporting person was granted 19,425 restricted stock units, vesting in four equal installments every six months beginning on the six month anniversary of the grant date.

Remarks:

Officer title: Executive Vice President, Chief Legal and Compliance Officer and Corporate Secretary